Trillium Therapeutics Stock Forecast, Price & News

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Trillium Therapeutics in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Trillium Therapeutics stock.
View analyst ratings for Trillium Therapeutics or view top-rated stocks.

Wall Street analysts have given Trillium Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Trillium Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Trillium Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, May 21st 2021.
View our earnings forecast for Trillium Therapeutics.

Trillium Therapeutics Inc. (NASDAQ:TRIL) issued its quarterly earnings data on Thursday, March, 18th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.14) by $0.11. The biotechnology company earned $0.03 million during the quarter.
View Trillium Therapeutics' earnings history.

Trillium Therapeutics' stock was trading at $5.19 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, TRIL stock has increased by 100.0% and is now trading at $10.38.
View which stocks have been most impacted by COVID-19.

7 equities research analysts have issued twelve-month target prices for Trillium Therapeutics' shares. Their forecasts range from $14.00 to $28.00. On average, they anticipate Trillium Therapeutics' stock price to reach $21.83 in the next twelve months. This suggests a possible upside of 110.3% from the stock's current price.
View analysts' price targets for Trillium Therapeutics or view top-rated stocks among Wall Street analysts.

Some companies that are related to Trillium Therapeutics include I-Mab (IMAB), Arena Pharmaceuticals (ARNA), Emergent BioSolutions (EBS), Hypera (HYPMY), Agios Pharmaceuticals (AGIO), Atea Pharmaceuticals (AVIR), Turning Point Therapeutics (TPTX), Apellis Pharmaceuticals (APLS), Nektar Therapeutics (NKTR), Insmed (INSM), Legend Biotech (LEGN), ACADIA Pharmaceuticals (ACAD), PTC Therapeutics (PTCT), Reata Pharmaceuticals (RETA) and InnovAge (INNV).
View all of TRIL's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Trillium Therapeutics investors own include Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Energy Transfer (ET), Gilead Sciences (GILD), VBI Vaccines (VBIV), Agile Therapeutics (AGRX), Actinium Pharmaceuticals (ATNM) and Evoke Pharma (EVOK).

Trillium Therapeutics trades on the NASDAQ under the ticker symbol "TRIL."

Trillium Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include FNY Investment Advisers LLC (0.04%). Company insiders that own Trillium Therapeutics stock include James T Parsons, Jan Skvarka, Penka Petrova and Robert Uger.
View institutional ownership trends for Trillium Therapeutics.

TRIL stock was sold by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC. Company insiders that have sold Trillium Therapeutics company stock in the last year include James T Parsons, Jan Skvarka, Penka Petrova, and Robert Uger.
View insider buying and selling activity for Trillium Therapeutics or view top insider-selling stocks.

Shares of TRIL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TRIL stock can currently be purchased for approximately $10.38.

Trillium Therapeutics has a market capitalization of $1.07 billion and generates $120,000.00 in revenue each year. The biotechnology company earns $-41,620,000.00 in net income (profit) each year or ($1.38) on an earnings per share basis.

The official website for Trillium Therapeutics is www.trilliumtherapeutics.com.

Trillium Therapeutics is headquartered at 2488 DUNWIN DRIVE, MISSISSAUGA A6, L5L 1J9.

Trillium Therapeutics' mailing address is 2488 DUNWIN DRIVE, MISSISSAUGA A6, L5L 1J9. The biotechnology company can be reached via phone at (416) 595-0627 or via email at [email protected]